Eikon Therapeutics Announces $517.8 Million Series B Raise And Expansion Of Executive Leadership Team
Eikon Therapeutics Announces $517.8 Million Series B Raise And Expansion Of Executive Leadership Team
01/06/22, 12:00 PM
Location
haywardMoney raised
$518 million
Industry
health care
Round Type
series b
Eikon Therapeutics, Inc., a pioneer in the application of live-cell super-resolution microscopy to drug discovery, today announced that it has closed a $517.8 million Series B financing. Since its founding two years ago, Eikon Therapeutics has raised more than $668 million to advance its mission of inventing new therapies that address grievous illness.
Company Info
Location
hayward, california, united states
Additional Info
Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and automation with the goal of bringing important new medicines to patients suffering from grievous illness. Scientists at Eikon measure the real-time movement of individual proteins in living cells to develop differentiated therapeutics. Eikon is based in Hayward, California and can be found online via our website or on Twitter or LinkedIn.